Alzheimer's Disease and Dementia
Alzheimer's disease is a type of dementia that causes problems with memory, thinking and behavior, interfering with daily tasks over time. If you or someone you love have been diagnosed with dementia caused by Alzheimer's disease, you'll be in good hands at Jefferson.
Physicians throughout the Delaware Valley and around the world refer patients with Alzheimer's disease to Jefferson Hospital for Neuroscience. We interact with patients very early in the disease progression, when impairment is typically mild. We also deliver state-of-the-art care, build care-giving skills and help caregivers connect with community support and plan for the future.
We support both you and your family in managing Alzheimer's disease to help delay the onset of debilitating conditions that could lessen your independence. And Jefferson Hospital for Neuroscience is advancing fundamental knowledge of the disease and leading the pursuit for new treatments through research and clinical trials.
Testing New Treatments for Alzheimer's Disease
We are constantly evaluating new medications that may slow the course of Alzheimer's disease. One promising medication is designed to reduce the level of a small protein believed to be involved in causing Alzheimer’s disease.
In addition, we are working on another encouraging study that tests whether increasing participation in cognitive, physical and/or social activities prevents cognitive decline in older African Americans with Mild Cognitive Impairment (MCI).
Participation in Alzheimer's Disease Clinical Trials
Although there is no cure for Alzheimer's disease, our goal is to provide accurate diagnoses and state-of-the-art treatment. We are also involved in basic science research that is advancing fundamental knowledge of dementia-related disorders and paving the way for new methods of treatment.
At Jefferson Hospital for Neuroscience, patients with Alzheimer's disease can participate in clinical trials with promising investigational treatments for the disease. Most of these studies are multicenter, multiyear trials that have already met a number of rigorous standards for safety and efficacy and have shown favorable effects on memory.
For many patients and their families, participation not only offers the hope of slowing the disease but also represents a chance to share personal experience and contribute to new scientific knowledge. Patients who agree to participate must be able to assent to the study, and caregivers who support that participation act as surrogate decision-makers and provide informed consent.
To learn more about clinical trials for Alzheimer's disease, please contact Megan Kelley, Clinical Research Coordinator, at 215-503-1243.